Presentation highlights first clinical study of ATX-295, a potentially best-in-class oral KIF18A inhibitor, in patients with advanced or metastatic solid tumors LEXINGTON, Mass., May 21, 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results